Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin in Newly Diagnosed FLT3-mutated AML
NCT03280030Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2018
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of midostaurin in acute myeloid leukemia (AML), sponsored by Novartis. Started Apr 2018; status: completed.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03280030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03280030.